The predictive role of ERCC1 status in oxaliplatin based neoadjuvant treatment for metastatic colorectal cancer (mCRC) to the liver

被引：0
|
作者：
Geva, Ravit
Shamai, Sivan
Barazovsky, Eli
Ben-Haim, Mend
Shmueli, Einat
机构：
来源：
TUMOR BIOLOGY | 2012年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：57 / 57
页数：1
相关论文
共 50 条
  • [1] The Predictive Role of ERCC1 Status in Oxaliplatin Based Neoadjuvant Therapy for Metastatic Colorectal Cancer (mCRC) to the Liver
    Geva, Ravit
    Shamai, Sivan
    Brazowsky, Eli
    Paoulas, Michael
    Ben-Haim, Mendi
    Johnstone, Elaine
    Alex, Beny
    Shacham-Shmueli, Einat
    [J]. CANCER INVESTIGATION, 2015, 33 (04) : 89 - 97
  • [2] ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt
    Kassem, Amira B.
    Salem, Salem Eid
    Abdelrahim, Mohamed E.
    Said, Amira S. A.
    Salahuddin, Ahmad
    Hussein, Marwa Mahmoud
    Bahnassy, Abeer A.
    [J]. EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2017, 102 (01) : 78 - 85
  • [3] Biological and predictive role of ERCC1 polymorphisms in cancer
    Formica, V.
    Doldo, E.
    Antonetti, F. R.
    Nardecchia, A.
    Ferroni, P.
    Riondino, S.
    Morelli, C.
    Arkenau, H. T.
    Guadagni, F.
    Orlandi, A.
    Roselli, M.
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 111 : 133 - 143
  • [4] Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer
    H Baba
    M Watanabe
    H Okabe
    Y Miyamoto
    Y Sakamoto
    Y Baba
    M Iwatsuki
    A Chikamoto
    T Beppu
    [J]. British Journal of Cancer, 2012, 107 : 1950 - 1955
  • [5] Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer
    Baba, H.
    Watanabe, M.
    Okabe, H.
    Miyamoto, Y.
    Sakamoto, Y.
    Baba, Y.
    Iwatsuki, M.
    Chikamoto, A.
    Beppu, T.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 107 (12) : 1950 - 1955
  • [6] Changes in expression levels of excision repair cross-complementing group 1 (ERCC1) and dihydropyrimidine dehydrogenase (DPD) during firstline oxaliplatin-based treatment of advanced metastatic colorectal cancer (mCRC).
    Baba, Hideo
    Watanabe, Masayuki
    Okabe, Hirohisa
    Miyamoto, Yuji
    Sakamoto, Yasuo
    Baba, Yoshifumi
    Iwatsuki, Masaaki
    Chikamoto, Akira
    Beppu, Toru
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [7] ERCC1, KRAS mutation, redox status, and oxaliplatin sensitivity in colorectal cancer: "Radical" change in an old model
    Orlandi, Armando
    Di Salvatore, Mariantonietta
    Basso, Michele
    Bagala, Cinzia
    Strippoli, Antonia
    Plastino, Francesca
    Dadduzio, Enzo
    Di Lascio, Simona
    Cursio, Elisabetta
    Amoruso, Alessia
    Rodriquenz, Mariagrazia
    Cassano, Alessandra
    Astone, Antonio
    Barone, Carlo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Oxaliplatin: role in the treatment of metastatic colorectal cancer
    Louvet, C
    deGramont, A
    [J]. REVUE DE MEDECINE INTERNE, 1997, 18 : S368 - S371
  • [9] IMPACT OF KRAS MUTATION & ERCC1 OVER-EXPRESSION ON OXALIPLATIN-BASED CHEMOTHERAPY IN METASTATIC COLORECTAL CANCER PATIENTS.
    Park, S.
    Lee, I.
    [J]. DISEASES OF THE COLON & RECTUM, 2017, 60 (06) : E342 - E342
  • [10] ERCC1 and ERCC2 polymorphisms predict the clinical outcomes of oxaliplatin-based adjuvant chemotherapy in colorectal cancer
    Shi, Lei
    Wang, Ran
    Wu, Wen-ming
    Huang, Yi-fei
    [J]. AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY, 2012, 6 (32): : 2429 - 2432
12345